Summit Therapeutics (SMMT) Enterprise Value (2017 - 2026)

Summit Therapeutics (SMMT) has reported Enterprise Value for 10 consecutive years, with -$690.7 million the latest figure, recorded in Q2 2026.

• Quarterly Enterprise Value fell 131.62% year-over-year to -$690.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$690.7 million (down 131.62% YoY) and the FY2025 annual result came in at -$713.4 million, down 73.02% from the prior year.
• Enterprise Value declined to -$690.7 million in Q2 2026 per SMMT's latest filing, from -$598.7 million in the prior quarter.
• Over the last five years, Enterprise Value for SMMT reached as high as -$28.8 million in Q2 2024 and fell as low as -$713.4 million in Q4 2025.
• A 5-year average of -$302.9 million and a median of -$226.9 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 88.99% — and 2025, when it plunged 937.04%.
• Year by year, Enterprise Value stood at -$648.6 million in 2022, then jumped by 88.99% to -$71.4 million in 2023, then sank by 477.32% to -$412.3 million in 2024, then slumped by 73.02% to -$713.4 million in 2025, then climbed by 3.19% to -$690.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$690.7 million, -$598.7 million, and -$713.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.